Women's Journal — Health, Beauty, Fitness & Lifestyle
Air Pollution Linked to Faster Bone Loss in Postmenopausal Women
A new study on air pollution bone loss postmenopausal women found that long-term exposure to air pollution was associated with greater bone loss among postmenopausal women, with stronger effects observed in those living in lower-income neighborhoods. The findings provide new evidence that environmental exposures and neighborhood socioeconomic conditions may together influence bone health and fracture risk. Key Takeaways Researchers found an association between long-term air pollution exposure and greater bone loss in postmenopausal women. The association was stronger among women living in lower-income neighborhoods. The study examined both environmental pollution exposure and neighborhood socioeconomic conditions. The findings add evidence that social and environmental factors may jointly influence bone health. Researchers reported that prolonged exposure to air pollution was associated with increased bone loss among postmenopausal women. The association was observed after evaluating participants over time and comparing bone health outcomes with measures of long-term exposure to air pollutants. Bone loss is a significant health concern after menopause because declining estrogen levels accelerate reductions in bone mineral density. Lower bone density increases the likelihood of osteoporosis and fractures, particularly involving the hip, spine, and wrist. The study found that women living in lower-income neighborhoods experienced stronger associations between air pollution exposure
Study Finds Heart Health Risks Rise During Perimenopause
Perimenopause heart health concerns are receiving renewed attention after researchers identified evidence that cardiovascular changes in women may begin earlier than many physicians previously recognized. The findings emerged from a large-scale study examining metabolic and vascular indicators among women transitioning into menopause, with researchers observing measurable shifts in cholesterol, blood sugar regulation, and blood vessel function during the perimenopausal stage. The study focused on women who had not yet reached menopause but were already experiencing hormonal fluctuations associated with the transition period. Researchers analyzed cardiovascular markers over time and found that several risk indicators linked to heart disease appeared before menopause officially began. The findings are prompting additional discussion among medical professionals about earlier screening and preventive care strategies for women entering midlife. Heart disease remains one of the leading causes of death among women globally. While menopause has long been associated with increased cardiovascular risk, the latest findings suggest the biological changes contributing to that risk may start years earlier than previously emphasized in clinical practice. Researchers involved in the study examined how shifting estrogen levels during perimenopause may influence vascular function, inflammation, and metabolic health. The research adds to a growing body of evidence connecting hormonal changes to
NEWS
FITNESS
LIFESTYLE
NHS Guidance Calls for PMOS Checks in Women
PMOS checks could become more consistent under new draft guidance from the National Institute for Health and Care Excellence, which calls for closer assessment of women and girls with irregular periods, hormone-related symptoms, and related long-term health risks. The guidance is still under consultation, with final publication scheduled for December 2026. Key Takeaways NICE draft guidance calls for PMOS checks in people aged 10 and over with suspected symptoms. PMOS is the new name for polycystic ovary syndrome, previously known as PCOS. Irregular periods, androgen-related symptoms, and metabolic health concerns are central to the guidance. NICE recommends annual reviews for people diagnosed with PMOS. The draft consultation runs from July 1 to August 11, 2026. PMOS, or polyendocrine metabolic ovarian syndrome, is the newer name for the condition long known as polycystic ovary syndrome. The name change was formally introduced in May 2026 after international medical groups said the older term placed too much emphasis on ovarian cysts and did not fully describe the condition’s endocrine and metabolic features. The National Institute for Health and Care Excellence, known as NICE, has now published draft guidance on PMOS for consultation. The draft runs from July 1 to August 11, 2026,
BEAUTY
OPINION
